FIELD: pharmaceutics.
SUBSTANCE: the set of components is suggested containing: (a) pharmaceutical preparation including low-molecular thrombin inhibitor or its pharmaceutically acceptable derivative in the mixture with pharmaceutically acceptable adjuvant, solvent or carrier; and (b) pharmaceutical preparation including pre-medicine of low-molecular thrombin inhibitor or pharmaceutically acceptable derivative of this pre-medicine in the mixture with pharmaceutically acceptable adjuvant, solvent or carrier, where components (a) and (b), each of them, should be taken in the form suitable to be introduced together; it is, also, suggested to apply this set of components for treating the state at which it is necessary or preferably to inhibit thrombin. The innovation enables to treat thrombotic states such as thrombosis of deep veins and pulmonary embolism.
EFFECT: higher efficiency of application.
30 cl, 1 tbl
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL COMBINATIONS | 2002 |
|
RU2331422C2 |
PHARMACEUTICAL COMBINATIONS | 2000 |
|
RU2242232C2 |
PHARMACEUTIC PREPARATION CONTAINING CARBOXYPEPTIDASE U INHIBITOR AND THAT OF THROMBIN | 2000 |
|
RU2242992C2 |
ESSENTIALLY CRYSTALLINE MELAGATRAN FORM | 2000 |
|
RU2243973C2 |
PRODRUGS OF THROMBIN INHIBITORS | 1996 |
|
RU2176644C2 |
ALMOND ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITOR | 2002 |
|
RU2341516C2 |
IMMEDIATE-RELEASED TABLET | 1999 |
|
RU2252751C2 |
THROMBIN INHIBITORS, PHARMACEUTICAL COMPOSITION BASED ON THEREOF, METHOD OF TREATMENT, METHOD OF THEIR SYNTHESIS (VERSIONS) AND PROTECTED DERIVATIVE | 1996 |
|
RU2176645C2 |
THROMBIN INHIBITOR-CONTAINING AQUEOUS SOLUTION FOR NONPARENTERAL ADMINISTRATION SHOWING STABILITY AT STORAGE | 1995 |
|
RU2164803C2 |
PHARMACEUTICAL COMPOSITION | 2002 |
|
RU2323006C2 |
Authors
Dates
2005-05-27—Published
2000-04-19—Filed